Endo Pharmaceuticals has responded to the FDA's request for more information on the company's application for the investigational painkillers oxymorphone extended-release (ER) and immediate-release (IR) tablets. The FDA requested additional clinical trials to further confirm the safety and efficacy of the products after issuing approval letters in October 2003. If its product is approved, Endo said it's prepared to launch oxymorphone in the second half of 2006.
Examining Trends in Long-Term Opioid Use, Importance of Pharmacist-Physician Collaboration
March 27th 2024At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.